Puma Biotechnology
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology Third Quarter 2022 Earnings: Beats Expectations
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
Can Puma Biotechnology Inc (PBYI) Stock Rise to the Top of Healthcare Sector Tuesday?
Puma Biotechnology: Too Little, Too Late, Too Much Of A Bad Side Effect (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology reports interim SUMMIT results for neratinib | Drug Discovery News
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Puma Biotechnology
Former Puma Biotechnology exec is accused of making $1.2 million from insider trading - Los Angeles Times
Puma Biotechnology Surging
Former Puma Biotech executive gets U.S. prison term for insider trading | Reuters.com
Articles with Puma Biotechnology
Puma Biotech plunges on drug side effects
Puma Biotechnology up 15% after quarterly earnings beats (NASDAQ:PBYI) | Seeking Alpha
PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence
Puma Biotechnology
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Puma Biotechnology
Puma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote - TheStreet
Exhibitor Puma Biotechnology 11-6 - Scripps CME Connection
Puma Biotechnology
Puma Biotechnology
